Objectives Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy and safety in patients with moderate-to-severe rheumatoid arthritis (RA) who exhibited inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs-IR) by a phase III clinical trial (NCT04333771). This post-hoc study focused on patient-reported outcomes (PROs) using the data of this trial, aiming to comprehensively assess the treatment’s impact on patients’ quality-of-life and symptom perception. Methods Patients were randomized (1:1:1) to receive once daily ivarmacitinib 4 mg (N = 189), ivarmacitinib 8 mg (N = 189) or placebo (N = 188). At week 24, patients with placebo switched to ivarmacitinib 4 mg for an additional 28 weeks, while the others continued their initial dosage. PROs included morning stiffness duration and severity, Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient Global Assessment of Disease Activity (PtGA), 36-Item Short Form Health Survey (SF-36), and pain by visual analog scale. Results Ivarmacitinib 4 mg and 8 mg demonstrated significantly higher rates of HAQ-DI improvement ≥ 0.22 compared to placebo from week 2 to 24 (all P < 0.05). Meanwhile, ivarmacitinib 4 mg and 8 mg significantly improved morning stiffness duration and severity, HAQ-DI score, SF-36 physical and mental component score, PtGA, and pain at week 24 compared to placebo (all P < 0.05). From week 24 to 52, all PROs were sustainedly improved by ivarmacitinib 4 and 8 mg; patients who switched from placebo to ivarmacitinib 4 mg at week 24 also achieved substantial improvements in PROs. Conclusion Ivarmacitinib significantly and sustained improves PROs in patients with moderate-to-severe RA with csDMARDs-IR. <Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry align="left" nameend="c2" namest="c1"> Key Points • In patients with moderate-to-severe RA with csDMARDs-IR, ivarmacitinib, a novel selective JAK-1 inhibitor, improved various dimensions of PROs compared with placebo, including patient-reported symptoms of RA, overall physical functioning, quality-of-life, and spiritual well-being. • From week 24 to week 52, patients who switched from placebo to ivarmacitinib experienced substantial improvements in all PROs. • From week 24 to week 52, patients who continued ivarmacitinib treatment showed sustained improvements in PROs. </entry> </row> </tbody> </tgroup> </Table>

Effect of ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis: a post-hoc analysis of a phase III trial

期刊论文
发表日期：

2026年4月1日

查看全文

Nannan Xia,
Lijuan Zhu,
Weifeng Zhang,
Luyue Zhang,
Lixin Feng,
Zhijuan Ren,
Yuqing Luo,
Nan Wang,
Lei Yang,
Haixue Dai,
Shanshan Yin,
Tan Lu

摘要

Objectives

Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy and safety in patients with moderate-to-severe rheumatoid arthritis (RA) who exhibited inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs-IR) by a phase III clinical trial (NCT04333771). This post-hoc study focused on patient-reported outcomes (PROs) using the data of this trial, aiming to comprehensively assess the treatment’s impact on patients’ quality-of-life and symptom perception.

Methods

Patients were randomized (1:1:1) to receive once daily ivarmacitinib 4 mg (N = 189), ivarmacitinib 8 mg (N = 189) or placebo (N = 188). At week 24, patients with placebo switched to ivarmacitinib 4 mg for an additional 28 weeks, while the others continued their initial dosage. PROs included morning stiffness duration and severity, Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient Global Assessment of Disease Activity (PtGA), 36-Item Short Form Health Survey (SF-36), and pain by visual analog scale.

Results

Ivarmacitinib 4 mg and 8 mg demonstrated significantly higher rates of HAQ-DI improvement ≥ 0.22 compared to placebo from week 2 to 24 (all P < 0.05). Meanwhile, ivarmacitinib 4 mg and 8 mg significantly improved morning stiffness duration and severity, HAQ-DI score, SF-36 physical and mental component score, PtGA, and pain at week 24 compared to placebo (all P < 0.05). From week 24 to 52, all PROs were sustainedly improved by ivarmacitinib 4 and 8 mg; patients who switched from placebo to ivarmacitinib 4 mg at week 24 also achieved substantial improvements in PROs.

Conclusion

Ivarmacitinib significantly and sustained improves PROs in patients with moderate-to-severe RA with csDMARDs-IR.

Key Points

• In patients with moderate-to-severe RA with csDMARDs-IR, ivarmacitinib, a novel selective JAK-1 inhibitor, improved various dimensions of PROs compared with placebo, including patient-reported symptoms of RA, overall physical functioning, quality-of-life, and spiritual well-being.

• From week 24 to week 52, patients who switched from placebo to ivarmacitinib experienced substantial improvements in all PROs.

• From week 24 to week 52, patients who continued ivarmacitinib treatment showed sustained improvements in PROs.